Tue, Sep 16, 2014, 10:57 AM EDT - U.S. Markets close in 5 hrs 3 mins

Recent

% | $
Quotes you view appear here for quick access.

Market Vectors Junior Gold Mine Message Board

jrdelane 735 posts  |  Last Activity: Sep 12, 2014 12:04 AM Member since: Dec 5, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • jrdelane jrdelane Jun 18, 2014 5:57 PM Flag

    Can we just reach $40 first? And what calendar year is this projected to be?

  • Looks like they've got AE-37 to compete with Neuvax. Copied this from their site: AE37 is not the only peptide vaccine in development in the adjuvant setting. Galena BioPharma's NeuVax (E75) is currently in phase III trials for the treatment of various cancers. NeuVax is also derived from the HER2 protein but is MHC Class I restricted. Thus far, there is evidence of prevention of disease recurrence with NeuVax as well. Another vaccine, GP2 (which like E75 is a HER2-derived vaccine), is being developed by Antigen Express. - See more at: http://www.cancernetwork.com/breast-cancer/asco-ae37-peptide-vaccine-may-help-prevent-breast-cancer-recurrence#sthash.EtEq7Kaw.dupe

    Sentiment: Strong Buy

  • Reply to

    congrats to Donaldtay1 on his good news

    by brightsmile213 Aug 25, 2014 4:29 PM
    jrdelane jrdelane Aug 25, 2014 11:48 PM Flag

    Our money pays psychic dividends now, real $returns will come later, delayed gratification is a Godly thing bashers can't grasp!

    Sentiment: Strong Buy

  • jrdelane by jrdelane Jun 27, 2014 2:30 PM Flag

    OK, so MM did the quick morning run to pick up shares via stop losses, now it's time to resume the run up. Good luck longs, time is on our side, we aren't paying to borrow shares, and the trend is our friend.

    Sentiment: Strong Buy

  • No other MS drug currently on the market has demonstrated
    significant neuroprotection and the potential positive impact on cognition. Dr. Voskuhl and her potential partners
    are very intrigued. In fact, Dr. Voskuhl emailed me yesterday, stating only further emphasis is the fact that this
    data leads the field into new paths of treatment for MS that are not merely anti-inflammatory but also
    neuroprotective. Such neuroprotective effects of Trimesta may ultimately be relevant to Alzheimer’s disease and
    other neurodegenerative diseases characterized by cognitive decline – unquote. We look forward to evaluating
    this exciting clinical result as well as exploring potential unique regulatory strategies going forward.
    In summary, the multiple positive efficacy signals from this placebo-controlled study are strong. Neurologists
    and MS specialists saw exactly what they hoped to see from this study and more in the area of cognitive
    improvement. Dr. Voskuhl, Synthetic Biologics, as well as several potential partners believe we are on the right
    track in developing Trimesta as an adjunctive MS therapy for women. We look forward to updating shareholders
    on our discussions with potential MS partners as well as our plans to advance Trimesta in the clinic based on
    these clinically significant Phase II results.

    Sentiment: Strong Buy

  • One post about this, don't give him the attention, that is what he wants, ignore him, don't red thumb or read his posts. Let him wither from zero attention, and quit wasting board space posting about him, please! Talk about your investment, or the company, or the market, but not personalities. Small minds do that, is that how you want to appear, same as him?

    Sentiment: Strong Buy

  • Reply to

    Since April

    by dolfan2323 Jul 16, 2014 1:39 PM
    jrdelane jrdelane Jul 16, 2014 4:44 PM Flag

    You don't consider the shelf registration to be "bad news"? Granted, they haven't diluted yet, but registering the intent to dilute to that magnitude is not greeted with enthusiasm by investors. I think it qualifies as bad news.

    Sentiment: Hold

  • Unless you were expecting the quick retrace up like the last rally to .97, hopefully you signed on for a long term investment. This is going to take some time to develop, you can see we are reaching the designated targets as Nasrat said. I did hear him say he is open to whatever is best for creating shareholder vlue, and if that means partnership or buyout, he would just retire early if taken out. I like his transparency, and further he stated he is with ELTP as long as they need him (to advance the pipeline to complete what they've started). He's all about creating shareholder value, because he is paid in shares and not cash. I think the man has a lot of integrity, and is laying down the foundations of a very successful company. I thought he handled callers questions well, and that his analogy of the mansion without a roof was excellent. When he arrived, ELITE had to have the roof added. Now the Company has straightened out their balance sheet and they have the cash to do what they need to do. Give the man credit, and time to execute the business plan.

    Sentiment: Hold

  • Elite's ART technology can be applied to many drugs and de-risk opioids. The time is right, the FDA and politicians want safer medications, anti-abuse deterrent ART technology will not be denied!

    March 27, 2014: Governor Patrick Bans Zohydro

    Governor Deval Patrick issued a Declaration of Emergency regarding opioid addiction and concluded that "an emergency exists which is detrimental to the public health" in Massachusetts. In conjunction with this declaration and on the same day, Massachusetts Department of Public Health Commissioner Cheryl Bartlett approved an emergency order banning Zohydro ER's from being prescribed, dispensed, and administered.

    Governor Patrick's reasoning for declaring emergency on opioid addiction in his state centered on three citations: 1) 668 Massachusetts residents died from unintentional opioid overdoses in 2012, 2) opioid abuse has increased due to the proliferation of prescriptions of opioid pain relievers, and 3) opioid use serves as gateway to heroin use.

    Sentiment: Strong Buy

  • jrdelane by jrdelane Jun 24, 2014 12:20 PM Flag

    What I see is our stock is in demand and is getting bought heavily on the dips. I saw it here and agree that the new floor is now $0.42. Today's lower open gives some new shareholders a nice entry and also gives a healthy breather to the share price, up over 20% in two weeks. I'd rather see a more gradual gain in our share price than go parabolic and not be able to hold it. This is going to be a huge year for Elite, anyone reading this, if you're long you are due congratulations for seeing this. If you are short, I offer my condolences because you are going to get buried if you don't cover and soon!

    Sentiment: Strong Buy

  • Reply to

    Is Dendreon a $360 Stock - Or Is That Too Low?

    by johny_orca Jun 18, 2014 9:59 PM
    jrdelane jrdelane Jun 19, 2014 11:56 AM Flag

    New investor today, bought shares at 2.05. Think we'll make us some good money here Orca?? You've been here a while, since before FDA approval, takes courage to stay the course given the landscape, short bashers and all. I have learned that betting on companies who have been brutally manipulated (that can't last forever), I think this one is about to find its footing and get back in the green. Go DnDn!

    Sentiment: Strong Buy

  • Reply to

    Is Dendreon a $360 Stock - Or Is That Too Low?

    by johny_orca Jun 18, 2014 9:59 PM
    jrdelane jrdelane Jun 19, 2014 3:47 PM Flag

    Doubled back when it dropped and doubled my stake, now averaging 2.03. In March 2013 the trade I did that month in Horizon Pharma buying shares at 2.10 to 2.62 reminds me of this situation with DNDN. Today HZNP is trading at 16.45. They had two FDA approved drugs and short bashers were saying they'd go bankrupt. Well, I took the risk and look how it turned out. Today I own 40,000 shares of HZNP, increased my stake as it went up. This is the time to buy, when there are huge opposing basher interests creating the illusion of failure, when the reality is this is where you will make your money. This is going to be bought out or it will thrive once revenues build in Europe and here. Believe it!

    Sentiment: Strong Buy

  • Reply to

    I am sick of rfwelsch mindless pumping...

    by diwannewyork Aug 11, 2014 8:37 AM
    jrdelane jrdelane Aug 11, 2014 3:30 PM Flag

    Yes, it's what makes a market, buyers and sellers. That poster has never added any value to this board. Thanks for all your informative posts. We've been tested, now is time to get rewarded, now meaning going forward way beyond this next conference call and into the next year or three.

  • Reply to

    Clarity on 2014 full year financials

    by rfwelsh Jun 17, 2014 8:33 PM
    jrdelane jrdelane Jun 17, 2014 9:03 PM Flag

    Great informative post, nice conviction you have to go that large. I know there are some very large retail investors here, you are among the largest who has posted here. How long have you owned ELTP shares, you seem to know their 'ropes' pretty well. I look forward to what lies ahead with great anticipation and a positive outlook. If you are willing to say, what is your price outlook going forward for ELTP?

    Sentiment: Strong Buy

  • This company is entering a good phase ahead, cited already here. My position just entered the green Zone first time since I started buying first lot at .70, then more as she bottomed. Good luck longs!

  • Reply to

    Bought More

    by kdalglish14 Aug 27, 2014 4:14 PM
    jrdelane jrdelane Aug 27, 2014 4:39 PM Flag

    I agree, left and came back to see we only lost a couple cents, after being down .07 I think of it as a win. The challenge between catalysts is always holding onto the gains, and with IDRA, the catalysts are so far apart, that's why the shorts have had their way with it. There's a lot of well informed investors here, in retail, glad they have done their DD and are willing to share their views here.

    Sentiment: Strong Buy

  • Always liked what I knew about this company and with it basing at the 200 dma, I couldn't resist, this one is poised for take off any day now. Looks like good things come to those who have patience, now I've got my first batch of shares. Will likely add on any weakness, but the way the chart looks I don't expect it going forward. Good luck longs!

    Sentiment: Strong Buy

  • Reply to

    4th day in a row for green

    by gordonhoochie Jun 18, 2014 9:53 PM
    jrdelane jrdelane Jun 20, 2014 12:26 PM Flag

    Today, Friday June 20th, is day 6 for green. We gapped up to open at .42 and filled the gap later in the morning. Volume definitely is getting stronger, we've traded 725,000 shares by 12:15 ET. Last Friday total volume was 591,393 for the entire session and we've got over 3.5 hours to go. Currently trading at .417. To give you a volume comparison, last April 30 when we traded up to to .51 volume was 5,183,550 shares. It's getting more exciting.

    Sentiment: Strong Buy

  • Reply to

    16 days still no data

    by gavin020207 Jul 17, 2014 12:41 AM
    jrdelane jrdelane Jul 21, 2014 11:02 AM Flag

    I was at the Angels baseball game yesterday against the Mariners, and it ended on the last pitch when the Angel's scored the winning run in the bottom of the 9th inning. To use an analogy, here we are in the early innings of the game, and you are wanting to score winning runs now! Let the game play out, this one has got the right elements for success, admit it or you wouldn't be here. Just can't force it, anyone ever tell you it takes patience to invest in biotech stocks?

  • Reply to

    Question for the Elite chartists

    by gordonhoochie Jun 18, 2014 9:51 PM
    jrdelane jrdelane Jun 19, 2014 2:11 AM Flag

    Here's my take...What I've been watching is a bullish wedge that has formed on the chart since May 1st. Right now we are at to top edge of resistance in the wedge. We've touched twice on the lower support, and right now is the third touch at the wedge's stop resistance line. A one penny move takes us through the wedge top boundary, but what we need is a decisive move, punching through and beyond, with volume. This kind of move is usually when a news or PR catalyst gives us a jolt of buying. If we get it, we are cleared for takeoff! Should this happen, we can move easily to the low 60 cent range in a matter of days or weeks.

    Sentiment: Strong Buy

GDXJ
38.17-0.37(-0.96%)10:56 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.